IRTG 1479 retreat 2025
Dec 01, 2025 – This year’s IRTG 1479 retreat took place from November 19th to 21st, 2025. The students visited the M3 Research Center, Eberhard Karls University Tübingen. This retreat gave our doctoral...
Oncogene-driven immune escape (OncoEscape)
Collaborative Research Centre 1479
The Collaborative Research Center (CRC) 1479 “Oncogene-driven immune escape” is a research consortium of clinical and basic tumor biologists and immunologist. Our CRC builds on the scientific hypothesis that oncogenic signalling and immune escape mechanisms are closely connected. This concept implies that targeting of oncogene-driven immune evasion could take treatment beyond palliative therapy towards cures for different types of cancer.
News
Publications
Fetsch V, Schwöbel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Köhler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Färber J, Braun LM, Zähringer A, Lübbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kühn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712.
Highlighted by: Chakraverty R. Menin inhibitors: a 2-in-1 defense versus AML immune evasion. Blood (2026) 147 (5): 482–483.
Duque-Afonso J, Rummelt C, Förster K, Zeiser R, Mougiakakos D. BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia. Lancet. 2026 Jan 23:S0140-6736(25)02515-2. doi: 10.1016/S0140-6736(25)02515-2. Epub ahead of print.
Traichel J, Metzger A, Walz M, Feuerstein R, Wohlfeil N, Metzger P, Marx L, Asdih C, Lindenthal A, Seger A, Schrimpf J, Nardella LL, Kowar S, Frew IJ, Halbach S, Kesselring R, Boerries M, Griffin R, Brummer T. Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo. Cancer Res Commun. 2026 Jan 22. doi: 10.1158/2767-9764.CRC-25-0599. Epub ahead of print.
More Publications
